Therapy for patients with non-small cell lung cancer in the Russian Federation: EPICLIN-Lung study

  • Authors: Tyulyandin SA1, Imyanitov EN2,3,4, Moiseyenko VM5, Ponomarenko DM6,7, Gurina LI8, Koroleva IA9,10, Karaseva VV11,12
  • Affiliations:
    1. N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
    2. N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation
    3. Saint Petersburg Pediatric University of the Ministry of Health of the Russian Federation
    4. I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation
    5. Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (oncological)
    6. Irkutsk Regional Oncological Dispensary
    7. Irkutsk State Medical Academy of Postgraduate Education
    8. Primorsky Regional Clinical Oncologic Dispensary
    9. Samara Regional Clinical Oncological Dispensary
    10. Medical University "Reaviz"
    11. AstraZeneca Russia
    12. N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
  • Issue: Vol 18, No 4 (2016)
  • Pages: 27-33
  • Section: Articles
  • URL: https://journals.rcsi.science/1815-1434/article/view/27084
  • ID: 27084

Cite item

Full Text

Abstract

The first epidemiological observational EPICLIN-Lung study in Russia is aimed at revealing the true incidence and the type of EGFR mutations in the Russian population of patients with non-small cell lung cancer (NSCLC), the connection with the main epidemiological parameters, the treatment approaches and outcomes in real clinical practice. The study was conducted in 33 oncology centers across 24 Russian regions; the study included 838 patients with histologically confirmed NSCLC. Most patients (63.2%) presented with advanced disease (stage III-IV patients) and Squamous-cell carcinoma (54.3%) and adenocarcinoma (31%) were the most prevalent histology types of NSCLC. Epidemiology of EGFR mutations in this NSCLC cohort was similar to other studies of NSCLC in Caucasian populations. EGFR mutations were identified in 10.1% of NSCLC patients included in this study, most of them were women (69.4%) and associated with adenocarcinoma histologically (58.8%) and 71.8% of these patients were never-smokers. The presence of EGFR mutations in tumor indicated the low risk for progression. The results of EPICLIN-Lung study would contribute to a better understanding of prognostic and predictive factors of NSCLC in Russian populations and that would help to choose the optimal therapy in routine clinical practice.

About the authors

S A Tyulyandin

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: stjulandin@mail.ru
д-р мед. наук, проф., зам. дир., зав. отд-нием клинической фармакологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E N Imyanitov

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation; Saint Petersburg Pediatric University of the Ministry of Health of the Russian Federation; I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. отд. биологии опухолевого роста ФГБУ НИИ онкологии им. Н.Н.Петрова, зав. каф. медицинской генетики ФГБОУ ВО СПбГПМУ, проф. каф. онкологии ФГБОУ ВО СЗГМУ им. И.И.Мечникова 197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68; 194100, Russian Federation, Saint Petersburg, ul. Litovskaia, d. 2; 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

V M Moiseyenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (oncological)

д-р мед. наук, проф., дир. ГБУЗ СПб КНпЦСВМП(о) 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68A

D M Ponomarenko

Irkutsk Regional Oncological Dispensary; Irkutsk State Medical Academy of Postgraduate Education

канд. мед. наук, ГБУЗ ИОД, зав. химиотерапевтическим отд-нием ГБОУ ДПО ИГМАПО 664035, Russian Federation, Irkutsk, ul. Frunze, d. 32; 664049, Russian Federation, Irkutsk, m/r Iubileinyi, d. 100

L I Gurina

Primorsky Regional Clinical Oncologic Dispensary

д-р мед. наук, зам. глав. врача по медицинской части ГБУЗ ПККОД 690105, Russian Federation, Vladivostok, ul. Russkaia, d. 59

I A Koroleva

Samara Regional Clinical Oncological Dispensary; Medical University "Reaviz"

д-р мед. наук, во время проведения данного исследования: ГБУЗ СОКОД. В настоящее время: ЧУ ОО ВО МУ «Реавиз» 443031, Russian Federation, Samara, ul. Solnechnaia, d. 50; 443030, Russian Federation, Samara, ul. Chkalova, d. 100

V V Karaseva

AstraZeneca Russia; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, медицинский отд. компании «АстраЗенека», рук. терапевтического направления; проф. каф. онкологии фак-та усовершенствования врачей ФГБОУ ВО РНИМУ им. Н.И.Пирогова 125284, Russian Federation, Moscow, ul. Begovaia, d. 3, str. 1; 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Клинические рекомендации по диагностике и лечению больных раком легкого. Ассоциация онкологов России. М., 2014.
  2. Гуторов С.Л. Химиотерапия метастатического немелкоклеточного рака легкого с отсутствием активирующих мутаций. Эффективная фармакотерапия. 2014; 57: 24-9.
  3. Kelly K, Gutierrez M.E, Giaccone G. Non - small cell lung cancer. Bethesda Hand book of Clinical Oncology. Ed. by Abraham et al. Wolter Kluwer, 2010.
  4. Hirsch F.R, Varella-Garcia M, Bunn P.A.Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo - controlled study in advanced non - small - cell lung cancer. J Clin Oncol 2006; 24 (31): 5034-42.
  5. Carrato A.J et al. Clinical management patterns and treatment outcomes in patients with non - small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 2014; 30 (3): 447-61.
  6. Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М., 2015.
  7. Paez J.G, Janne P.A, Lee J.C et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
  8. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
  9. Моисеенко В.М., Проценко С.А., Семенов И.И. и др. Применение Ирессы (гефитиниб) в качестве терапии первой линии для лечении неоперабельных аденокарцином легкого, содержащих мутацию в гене EGFR. Современная Онкология. 2010; 1 (12): 60-5.
  10. Водолажский Д.И. Связь мутаций гена EGFR с клинико - патологическими особенностями аденокарциномы легкого у пациентов юга России. Клин. медицина. 2014; 92 (7): 57-62.
  11. Еникеев Р. Ф. Тестирование EGFR-мутаций при раке легкого. Собственный опыт. Поволжский онкологический вестн. 2012; 4: 33-8.
  12. Perez-Moreno P, Brambilla E, Thomas R, Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012; 18: 2443-51.
  13. Тюляндин С.А., Полоцкий Б.Е. Тактика лечения немелкоклеточного рака легкого III стадии. Практическая онкология. 2006; 7 (3): 161-9.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies